Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Medicine
Pharma
Astellas, Otsuka, Samsung Biologics—Fierce Pharma Asia
Astellas' CLDN18.2 drug cleared the FDA. Otsuka reported positive readout in IgAN. Samsung Bio signed its largest contract to date. Plus more.
Angus Liu
Oct 25, 2024 8:43am
Hengrui, Sanofi and Aslan—Fierce Pharma Asia
Jul 19, 2024 9:48am
Inside the FDA concerns that sank Hengrui's PD-1 drug filing
Jul 16, 2024 4:50pm
Eisai, Takeda, BIOSECURE—Fierce Pharma Asia
Jul 12, 2024 9:05am
UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 combo
Jul 12, 2024 12:08am
China's Hengrui hit with Form 483 for manufacturing shortfalls
Jun 6, 2024 9:29am